** Abbott Laboratories ABT.N on Wednesday forecast 2025 profit in line with Wall Street estimates as it expects new medical device launches and growing demand for its glucose monitors to offset a hit from weakness in China and a stronger dollar

** Median PT of 28 brokerages covering the stock is $134 - data compiled by LSEG

HEALTHY ON GROWTH AND INNOVATION

** J.P. Morgan ("overweight") is bullish on ABT's organic sales growth outlook for 2025 and demand for glucose monitors

** RBC ("outperform," PT: $135) says ABT is well-positioned and expects continued growth driven by innovations and a strong product pipeline

** TD Cowen ("buy," PT: $135) expects ABT to continue to deliver growth across its various segments, driven by innovation and market expansion

** UBS ("buy," PT: $148) says outlook for organic sales growth appears 'conservative'

** "We believe the sustainability of ABT’s MedTech business growth trajectory remains underappreciated" - UBS

(Reporting by Rashika Singh in Bengaluru)

((rashika.singh@thomsonreuters.com))